Risk Factor Management Before and After Atrial Fibrillation Ablation.


Journal

Cardiac electrophysiology clinics
ISSN: 1877-9190
Titre abrégé: Card Electrophysiol Clin
Pays: United States
ID NLM: 101549998

Informations de publication

Date de publication:
06 2020
Historique:
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 29 6 2021
Statut: ppublish

Résumé

Atrial fibrillation (AF) is increasingly recognized as the cardiac electrophysiologic manifestation of a multifactorial systemic disease. Several risk factors for development of AF have been identified; many are modifiable. There is evidence to suggest that aggressive management of modifiable risk factors has potential to significantly reduce the burden of AF, before and after AF ablation. Specific risk factor management (RFM) clinics have been shown effective in conferring these benefits into tangible improvements in large cohorts of patients. This review discusses the evidence behind RFM as a key adjunctive management strategy alongside AF ablation and suggests a model for RFM in clinics.

Identifiants

pubmed: 32451099
pii: S1877-9182(20)30023-X
doi: 10.1016/j.ccep.2020.02.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-154

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure Financial disclosures: Dr D. Lau is supported by the Robert J. Craig Lectureship from the University of Adelaide. Dr P. Sanders is supported by a Practitioner Fellowships from the National Health and Medical Research Council of Australia and by the National Heart Foundation of Australia. Conflict of interest disclosures: Dr P. Sanders reports having served on the advisory board of Medtronic, Abbott Medical, Boston Scientific, CathRx, and PaceMate. Dr P. Sanders reports that the University of Adelaide has received on his behalf lecture and/or consulting fees from Medtronic, Abbott Medical, and Boston Scientific. Dr P. Sanders reports that the University of Adelaide has received on his behalf research funding from Medtronic, Abbott Medical, Boston Scientific, and MicroPort.

Auteurs

Jonathan P Ariyaratnam (JP)

Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.

Melissa Middeldorp (M)

Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.

Gijo Thomas (G)

Centre for Heart Rhythm Disorders, University of Adelaide, South Australian Health and Medical Research Institute (SAHMRI) Adelaide, SA 5000, Australia.

Jean Jacques Noubiap (JJ)

Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.

Dennis Lau (D)

Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.

Prashanthan Sanders (P)

Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia. Electronic address: prash.sanders@adelaide.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH